Experts Highlight Importance of Achieving R0 Resections in Cancer Surgery
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Ensuring Quality of Life in Chronic Myeloid Leukemia Populations
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Treatment Considerations and the Role of BCMA-Targeting CAR T in MM
Continuing discussion centered on a patient case, the panel discusses bispecific antibody combinations and the role of BCMA-targeting CAR T-cell therapies in relapsed/refractory multiple myeloma.
Patient Profile: A 60-Year-Old with Stage III KLC MM
Adriana Rossi, MD, presents the case of a 60-year-old patient with stage III kappa light chain multiple myeloma, and members of the panel provide their initial impressions.
Formulating Questions for Clinicians to Understand a CML Diagnosis
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Balancing a Family and an Emerging Career in Public Health
Public health researchers highlight how they learned to overcome and adapt to disparities observed during their careers.
Underlying Mechanisms and Signs of CRS
The panel discusses the mechanisms believed to cause cytokine release syndrome associated with CAR T-cell therapy and the signs and symptoms.
Treating Patients Referred to Academic Centers for CAR T
Focusing on the transition of patients from community practices to academic centers, the panel discusses the initial evaluation and treatment processes, focusing on bridging therapy for patients awaiting CAR T.
Identifying Potential Candidates for CAR T-Cell Therapy
A panel of experts on multiple myeloma introduce themselves and discuss the initial process of identifying patients who are potential candidates for CAR T-cell therapy.
Patient Profile 1: Managing CRS Following CAR T-Cell Therapy
Beth Faiman, CNP, PhD, presents the case of a 76-year-old woman with multiple myeloma who experienced cytokine release syndrome (CRS) following CAR T-cell therapy.
Defining Goals of Therapy in Chronic Myeloid Leukemia
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Public Health Policies May Impact Cancer Care Outcomes
Health economists discuss their interests in the outcomes observed from the Affordable Care Act and its impact on specific populations.
Mitigating Toxicity and Monitoring QOL in Chronic Myeloid Leukemia
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Determining Treatment Courses for a Chronic Myeloid Leukemia Diagnosis
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Incorporating Collaboration and Personalization of Treatment in Breast Cancer Care
The field of breast oncology is constantly evolving to include trial diversity and multidisciplinary care.
MM Treatment: CAR T-Cell Therapy Selection and Insurance Considerations
The panel discusses the utilization of CAR T-cell therapy for patients with multiple myeloma, highlighting treatment selection, sequencing, and insurance considerations.
Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM
The panel concludes its discussion with key takeaways on the evolving role of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.
Patient Profile: A 66-Year-Old with IgG Kappa MM
Binod Dhakal, MD, presents the case of a 66-year-old patient with IgG kappa multiple myeloma, and the panel discusses treatment considerations and decisions.
Learning to Overcome Barriers While Developing a Breast Oncology Career
Tiffany A. Traina, MD, and Sherry Shen, MD, discussed barriers they have had to overcome throughout their oncology careers.
